중환자 치료
지혈 관리 및 최적화
항섬유소용해제
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (새로운 창 열기)
Source: Lancet 2019;394(10210):1713-23.
Indexed: PubMed 31623894
DOI: 10.1016/S0140-6736(19)32233-0
Alternatives to allogeneic platelet transfusion. (새로운 창 열기)
Source: Br J Haematol 2016;175(3):381-92.
Indexed: PubMed 27650431
DOI: 10.1111/bjh.14338
Tranexamic acid: less bleeding and less thrombosis? (새로운 창 열기)
Source: Crit Care 2012;16(3):135.
Indexed: PubMed 22748073
DOI: 10.1186/cc11374
Tranexamic acid for reducing mortality in emergency and urgent surgery. (새로운 창 열기)
Source: Cochrane Database Syst Rev 2013;(1):CD010245.
Indexed: PubMed 23440847
DOI: 10.1002/14651858.CD010245.pub2
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (새로운 창 열기)
Source: Lancet 2011;377(9771):1096-101, 1101.e1-2.
Indexed: PubMed 21439633
DOI: 10.1016/S0140-6736(11)60278-X
Antifibrinolytic drugs for acute traumatic injury. (새로운 창 열기)
Source: Cochrane Database Syst Rev 2011;(1):CD004896.
Indexed: PubMed 21249666
DOI: 10.1002/14651858.CD004896.pub3
Use of tranexamic acid to reduce bleeding in burns surgery. (새로운 창 열기)
Source: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.
Indexed: PubMed 21983540
DOI: 10.1016/j.bjps.2011.09.028
Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (새로운 창 열기)
Source: Burns. 2022;48(3):522-28.
Indexed: PubMed 35339324
DOI: 10.1016/j.burns.2022.03.002
재조합활성응고인자 VII (rFVIIa)
Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (새로운 창 열기)
Source: J Blood Med 2011;2:131-4.
Indexed: PubMed 22287872
DOI: 10.2147/JBM.S21609
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (새로운 창 열기)
Source: Transfusion 2009;49 Suppl 5:240S-7S.
Indexed: PubMed 19954486
DOI: 10.1111/j.1537-2995.2008.01987.x
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (새로운 창 열기)
Source: Transfusion 2013;53 Suppl 1:91S-5S.
Indexed: PubMed 23301979
DOI: 10.1111/trf.12041
A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (새로운 창 열기)
Source: Am Surg 2005;71(5):414-5.
Indexed: PubMed 15986972
Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (새로운 창 열기)
Source: J Trauma 2010;69(3):489-500.
Indexed: PubMed 20838118
DOI: 10.1097/TA.0b013e3181edf36e
Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (새로운 창 열기)
Source: Ann Surg 2008;248(1):61-8.
Indexed: PubMed 18580208
DOI: 10.1097/SLA.0b013e318176c4ec
Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (새로운 창 열기)
Source: J Trauma 2006;61(4):1016-8.
Indexed: PubMed 17033583
DOI: 10.1097/01.ta.0000239261.48022.f1
Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (새로운 창 열기)
Source: ANZ J Surg 2013;83(3):155-60.
Indexed: PubMed 23035873
DOI: 10.1111/j.1445-2197.2012.06285.x
Recombinant factor VIIa in trauma patients with the 'triad of death.' (새로운 창 열기)
Source: Injury 2012;43(9):1409-14.
Indexed: PubMed 21345431
DOI: 10.1016/j.injury.2011.01.033
Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (새로운 창 열기)
Source: Injury 2008;39(9):1054-61.
Indexed: PubMed 18656871
DOI: 10.1016/j.injury.2008.03.032
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (새로운 창 열기)
Source: Anesthesiology 2003;98(6):1513-5.
Indexed: PubMed 12766668
응고인자농축물(Coagulation Factor Concentrates)
Alternatives to allogeneic platelet transfusion. (새로운 창 열기)
Source: Br J Haematol 2016;175(3):381-92.
Indexed: PubMed 27650431
DOI: 10.1111/bjh.14338
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (새로운 창 열기)
Source: Transfusion 2013;53 Suppl 1:91S-5S.
Indexed: PubMed 23301979
DOI: 10.1111/trf.12041
Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (새로운 창 열기)
Source: Thromb Res 2014;134(2):360-8.
Indexed: PubMed 24857189
DOI: 10.1016/j.thromres.2014.05.008
Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (새로운 창 열기)
Source: Br J Haematol 2013;160(2):228-36.
Indexed: PubMed 23151086
DOI: 10.1111/bjh.12118
Strategies to reduce the use of blood products: a European perspective. (새로운 창 열기)
Source: Curr Opin Anaesthesiol 2012;25(1):59-65.
Indexed: PubMed 22113184
DOI: 10.1097/ACO.0b013e32834dec98
데스모프레신
Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (새로운 창 열기)
Source: Anesthesiology 2008;109(6):1063-76.
Indexed: PubMed 19034103
DOI: 10.1097/ALN.0b013e31818db18b
Alternatives to allogeneic platelet transfusion. (새로운 창 열기)
Source: Br J Haematol 2016;175(3):381-92.
Indexed: PubMed 27650431
DOI: 10.1111/bjh.14338
Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (새로운 창 열기)
Source: Blood Rev 2014;28(3):95-102.
Indexed: PubMed 24703870
DOI: 10.1016/j.blre.2014.03.001
기타 제제
Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (새로운 창 열기)
Source: JAMA 1987;258(14):1916-9.
Indexed: PubMed 3656602
DOI: 10.1001/jama.1987.03400140078028
Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (새로운 창 열기)
Source: Blood Coagul Fibrinolysis 2002;13(1):49-52.
Indexed: PubMed 11994567
DOI: 10.1097/00001721-200201000-00007
국소지혈제(Topical Hemostatic Agents)
The use of fibrin sealant in burn operations. (새로운 창 열기)
Source: Surgery 2007;142(4 Suppl):S50-4.
Indexed: PubMed 18019939
DOI: 10.1016/j.surg.2007.06.026
Use of fibrin sealant in thermal injury. (새로운 창 열기)
Source: J Burn Care Rehabil 1997;18(5):429-34.
Indexed: PubMed 9313125
DOI: 10.1097/00004630-199709000-00011
외과 출혈 또는 응고장애성 출혈을 파악하는 점탄성(Viscoelastic) 검사
Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (새로운 창 열기)
Source: Br J Anaesth 2012;109(3):376-81.
Indexed: PubMed 22719014
DOI: 10.1093/bja/aes186
Transfusion in trauma: why and how should we change our current practice? (새로운 창 열기)
Source: Curr Opin Anaesthesiol 2009;22(2):305-12.
Indexed: PubMed 19390257
DOI: 10.1097/ACO.0b013e3283212c7c
Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (새로운 창 열기)
Source: Health Technol Assess 2015;19(58):1-228.
Indexed: PubMed 26215747
DOI: 10.3310/hta19580